 | • レポートコード：GIR-107A12500 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、腎性全身性線維症（NSF）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腎性全身性線維症（NSF）治療の種類別市場規模（血液レオロジー剤、免疫調節剤、アルキル化剤、キナーゼ阻害剤、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・腎性全身性線維症（NSF）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Sanofi、Allergan、Novartis、Johnson & Johnson、Bausch Health、Merck、Teva Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：血液レオロジー剤、免疫調節剤、アルキル化剤、キナーゼ阻害剤、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・腎性全身性線維症（NSF）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・腎性全身性線維症（NSF）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・腎性全身性線維症（NSF）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・腎性全身性線維症（NSF）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・腎性全身性線維症（NSF）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Nephrogenic Systemic Fibrosis (NSF) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Nephrogenic Systemic Fibrosis (NSF) Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Nephrogenic Systemic Fibrosis (NSF) Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Nephrogenic Systemic Fibrosis (NSF) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Hemorrheologic Agents
Immunomodulatory Drug
Alkylating Agents
Kinase Inhibitors
Others
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Pfizer
Sanofi
Allergan
Novartis
Johnson & Johnson
Bausch Health
Merck
Teva Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Nephrogenic Systemic Fibrosis (NSF) Treatment
1.2 Classification of Nephrogenic Systemic Fibrosis (NSF) Treatment by Type
1.2.1 Overview: Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Type in 2020
1.2.3 Hemorrheologic Agents
1.2.4 Immunomodulatory Drug
1.2.5 Alkylating Agents
1.2.6 Kinase Inhibitors
1.2.7 Others
1.3 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market by Application
1.3.1 Overview: Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size & Forecast
1.5 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast by Region
1.5.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Region, (2016-2021)
1.5.3 North America Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Drivers
1.6.2 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Restraints
1.6.3 Nephrogenic Systemic Fibrosis (NSF) Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.1.4 Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.2.4 Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Allergan
2.3.1 Allergan Details
2.3.2 Allergan Major Business
2.3.3 Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.3.4 Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Allergan Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.4.4 Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.5.4 Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Bausch Health
2.6.1 Bausch Health Details
2.6.2 Bausch Health Major Business
2.6.3 Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.6.4 Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Bausch Health Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.7.4 Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck Recent Developments and Future Plans
2.8 Teva Pharmaceuticals
2.8.1 Teva Pharmaceuticals Details
2.8.2 Teva Pharmaceuticals Major Business
2.8.3 Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
2.8.4 Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Teva Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Nephrogenic Systemic Fibrosis (NSF) Treatment Players Market Share
3.2.2 Top 10 Nephrogenic Systemic Fibrosis (NSF) Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Nephrogenic Systemic Fibrosis (NSF) Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Application (2016-2021)
5.2 Nephrogenic Systemic Fibrosis (NSF) Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2026)
6.2 North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2026)
6.3 North America Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Country
6.3.1 North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2026)
6.3.2 United States Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2026)
7.2 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2026)
7.3 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Country
7.3.1 Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2026)
7.3.2 Germany Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
7.3.3 France Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Region
8.3.1 Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Region (2016-2026)
8.3.2 China Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8.3.5 India Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2026)
9.2 South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2026)
9.3 South America Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Country
9.3.1 South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size by Country
10.3.1 Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Nephrogenic Systemic Fibrosis (NSF) Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 9. Pfizer Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 13. Sanofi Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Allergan Corporate Information, Head Office, and Major Competitors
Table 15. Allergan Major Business
Table 16. Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 17. Allergan Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 21. Novartis Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 23. Johnson & Johnson Major Business
Table 24. Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 25. Johnson & Johnson Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 27. Bausch Health Major Business
Table 28. Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 29. Bausch Health Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 33. Merck Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Teva Pharmaceuticals Major Business
Table 36. Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Product and Solutions
Table 37. Teva Pharmaceuticals Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) by Players (2019-2021)
Table 39. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Share by Players (2019-2021)
Table 40. Breakdown of Nephrogenic Systemic Fibrosis (NSF) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Nephrogenic Systemic Fibrosis (NSF) Treatment Players Head Office, Products and Services Provided
Table 42. Nephrogenic Systemic Fibrosis (NSF) Treatment Mergers & Acquisitions in the Past Five Years
Table 43. Nephrogenic Systemic Fibrosis (NSF) Treatment New Entrants and Expansion Plans
Table 44. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) by Type (2016-2021)
Table 45. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Share by Type (2016-2021)
Table 46. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Forecast by Type (2021-2026)
Table 47. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021)
Table 48. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Forecast by Application (2021-2026)
Table 49. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Nephrogenic Systemic Fibrosis (NSF) Treatment Picture
Figure 2. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Type in 2020
Figure 3. Hemorrheologic Agents
Figure 4. Immunomodulatory Drug
Figure 5. Alkylating Agents
Figure 6. Kinase Inhibitors
Figure 7. Others
Figure 8. Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Application in 2020
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Others Picture
Figure 12. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Region in 2020
Figure 16. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Nephrogenic Systemic Fibrosis (NSF) Treatment Market Drivers
Figure 22. Nephrogenic Systemic Fibrosis (NSF) Treatment Market Restraints
Figure 23. Nephrogenic Systemic Fibrosis (NSF) Treatment Market Trends
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Sanofi Recent Developments and Future Plans
Figure 26. Allergan Recent Developments and Future Plans
Figure 27. Novartis Recent Developments and Future Plans
Figure 28. Johnson & Johnson Recent Developments and Future Plans
Figure 29. Bausch Health Recent Developments and Future Plans
Figure 30. Merck Recent Developments and Future Plans
Figure 31. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 32. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Share by Players in 2020
Figure 33. Nephrogenic Systemic Fibrosis (NSF) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share in 2020
Figure 35. Global Top 10 Players Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Share by Type in 2020
Figure 38. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Share Forecast by Type (2021-2026)
Figure 39. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Share by Application in 2020
Figure 40. Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Share Forecast by Application (2021-2026)
Figure 41. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Type (2016-2026)
Figure 42. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Application (2016-2026)
Figure 43. North America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Country (2016-2026)
Figure 44. United States Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Type (2016-2026)
Figure 48. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Application (2016-2026)
Figure 49. Europe Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Country (2016-2026)
Figure 50. Germany Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Region (2016-2026)
Figure 58. China Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Type (2016-2026)
Figure 65. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Application (2016-2026)
Figure 66. South America Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Nephrogenic Systemic Fibrosis (NSF) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の腎性全身性線維症（NSF）治療市場予測（～2024年） Nephrogenic systemic fibrosis is a medical disorder which is extremely rare and which occurs among individuals who undergo exposure to an intravenous contrast material that contains gadolinium or in individuals that have reduced kidney function. Nephrogenic Systemic Fibrosis (NSF) Treatment involves…- 世界の全身性炎症反応症候群治療市場 2021：企業別、地域別、種類・用途別 The Systemic Inflammatory Response Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…
- 腎臓/腎線維症治療の世界市場… Scope of the Report: The global Kidney/Renal Fibrosis Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in …
- 世界の皮膚線維症治療市場予測（～2024年） Dermal fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor maybe derived from activated leukocytes, recruits macrophages and fibroblasts into the tissue and leads to the production of e…
- 皮膚線維症治療の世界市場 2019年版：種類別（免疫療法、コルチコステロイド、抗線維化薬、免疫グロブリン）、用途別（病院薬局、小売薬局、オンライン薬局） Scope of the Report: The global Cutaneous Fibrosis Treatment market is valued at 488.8 million USD in 2018 and is expected to reach 615.1 million USD by the end of 2024, growing at a CAGR of 5.9% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially…